Omeros (NASDAQ:OMER) Upgraded by StockNews.com to Hold Rating

Omeros (NASDAQ:OMER) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Other research analysts have also recently issued research reports about the company. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Omeros Stock Up 28.2 %

Shares of NASDAQ OMER opened at $7.73 on Wednesday. The firm has a market cap of $447.95 million, a P/E ratio of -2.82 and a beta of 1.47. Omeros has a twelve month low of $1.66 and a twelve month high of $7.85. The company has a 50 day moving average of $4.29 and a 200 day moving average of $4.16.

Institutional Trading of Omeros

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Omeros by 2.6% in the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Omeros in the 3rd quarter worth approximately $305,000. Barclays PLC boosted its holdings in shares of Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after buying an additional 51,873 shares during the last quarter. Bank of New York Mellon Corp grew its position in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 31,081 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in Omeros during the second quarter valued at approximately $105,000. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.